TRIM21, an enzyme involved in intracellular substrate degradation, can recognize viruses and bacteria that enter the cytosol when they are coated with antibodies. Just as it tags complex molecules for elimination, it can direct these infectious microorganisms to lysosomes through a mechanism its discoverers have termed antibody-directed xenophagy (ADX). Scientists at the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) in Cambridge, U.K., have identified the genes involved in this antibody-dependent degradation pathway, which acts as an antimicrobial process, and reported their findings in Molecular Cell on June 4, 2026.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Agilent, Coloplast, Cycle, Hopstem, Orthalign, QT, Reach, Royal, Sotio, Terremoto, Waters, Xenix.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Abbott, Alnylam, Alpha Tau, Astrazeneca, Axsome, Daiichi, Inceptive, Leica, Minimed, Nanodetection, Oligomerix Tolmar.
Clinical updates for biopharma and med tech, including data readouts and publications: Argenx, Cabaletta, JJP, J&J, Kura, Kyverna, Legend, Tenaya, TG, Transcode, Zenas.
Biopharma and med-tech companies raising money in public or private financings, including: Advanced Nanotherapies, Bluejay, Liminatus, Lixte, Medtronic, Mineralys, Nrx.
New hires and promotions in the biopharma and med-tech industries, including: Celularity, Cocrystal, Corrixr, Cue Biopharma, Defence, Jenavalve, Natera, Neuronetics, Noah, Ovid, Precision, Transverse.
The BioWorld Neurological Diseases Index (BNDI) ended May up 12.29% for the year, outpacing both the Nasdaq Biotechnology Index (up 4.95%) and the Dow Jones Industrial Average (up 6.18%), a reversal from 2025 when the BNDI trailed both broader benchmarks.
Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam.
The U.S. Supreme Court handed Hikma Pharmaceuticals and the entire generic industry a big victory June 4 with its 9-0 opinion ensuring the future of skinny labels and correcting the Federal Circuit’s flawed understanding of infringed inducement.
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous system thyroid hormone receptor agonist, or thyromimetic, is moving toward a registrational path and a clinical readout in major depressive disorder.
RSS
